Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Intrinsic Value
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one
FUSN
stock under the Base Case scenario is
0.74
USD.
Compared to the current market price of 21.4 USD,
Fusion Pharmaceuticals Inc
is
Overvalued by 97%.
Fusion Pharmaceuticals Inc's market capitalization is 1.7B USD.
FUSN stock price is 21.4 USD.
FUSN stock (0.74 USD) is 97% less than its price (21.4 USD).
FUSN. Open DCF Valuation
FUSN stock (0.74 USD) is 97% less than its price (21.4 USD). Open Relative Valuation
FUSN has upside potential of 3% compared to the average analyst price target.
Open Wall St Estimates
FUSN's ROE (Return on Equity) has increased in the last 3 years from -54% to -49%, and is approaching profitability.
FUSN's Revenue has grown by an exceptional 42% over the past 12 months.
FUSN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -134% to -209%, and is approaching profitability.
FUSN has negative Operating Income for the last twelve months.
FUSN has negative Net Income for the last twelve months.
FUSN's ROE (Return on Equity) for the past 12 months is negative and is equal to -49%.
FUSN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -209%.
FUSN's Revenue is forecast to grow at a rate of 64% per year over the next 3 years.
FUSN has negative Free Cash Flow for the last twelve months.
FUSN's D/E (Debt to Equity) is very low and is equal to 0.16.
FUSN's Altman Z-Score is very high and is equal to 4.24.
FUSN has negative three-year average ROE (Return on Equity): -39%. The company is not efficient at transforming stockholders' equity into net income.
FUSN has negative three-year average ROIC (Return on Invested Capital): -156%. The company is not efficient at using invested capital to generate operating income.
FUSN's short-term assets (243m USD) exceed its short-term liabilties (16m USD).
FUSN's long-term assets (286m USD) exceed its long-term liabilties (63m USD).
FUSN has negative Net Debt. This means that the company has more cash and short-term investments (234m USD) than debt (35m USD).
FUSN doesn't generate enough operating income (-99m USD) to safely cover interest payments on its debt (5m USD).
Valuation Backtest
Fusion Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
FUSN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Fusion Pharmaceuticals Inc
Balance Sheet Decomposition
Fusion Pharmaceuticals Inc
| Current Assets | 243.4m |
| Cash & Short-Term Investments | 233.6m |
| Receivables | 5.5m |
| Other Current Assets | 4.3m |
| Non-Current Assets | 42.4m |
| Long-Term Investments | 13.7m |
| PP&E | 23.9m |
| Other Non-Current Assets | 4.8m |
| Current Liabilities | 16.2m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 13.9m |
| Other Current Liabilities | 417k |
| Non-Current Liabilities | 47.1m |
| Long-Term Debt | 34.8m |
| Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
Fusion Pharmaceuticals Inc
|
Revenue
|
2.1m
USD
|
|
Operating Expenses
|
-101.3m
USD
|
|
Operating Income
|
-99.2m
USD
|
|
Other Expenses
|
4.3m
USD
|
|
Net Income
|
-94.9m
USD
|
Free Cash Flow Analysis
Fusion Pharmaceuticals Inc
FUSN Profitability Score
Profitability Due Diligence
Fusion Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Fusion Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
FUSN Solvency Score
Solvency Due Diligence
Fusion Pharmaceuticals Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Fusion Pharmaceuticals Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FUSN Price Targets Summary
Fusion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
FUSN
is 22.1 USD
with a low forecast of 20.2 USD and a high forecast of 25.2 USD.
Ownership
FUSN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
FUSN Price
Fusion Pharmaceuticals Inc
| Average Annual Return | -40.85% |
| Standard Deviation of Annual Returns | 16.91% |
| Max Drawdown | -89% |
| Market Capitalization | 1.7B USD |
| Shares Outstanding | 84 865 000 |
| Percentage of Shares Shorted | 6.5% |
FUSN News
Last Important Events
Fusion Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Fusion Pharmaceuticals Inc
Company Profile
Fusion Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Hamilton Ontario, Ontario and currently employs 86 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing radiopharmaceuticals as precision medicines. The firm has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company’s lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.
Contact
IPO
Employees
Officers
The intrinsic value of one
FUSN
stock under the Base Case scenario is
0.74
USD.
Compared to the current market price of 21.4 USD,
Fusion Pharmaceuticals Inc
is
Overvalued by 97%.
You don't have any saved screeners yet
